Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG trials. Overall, 80 out of 134 (60%) patients were NOTCH þ (NOTCH1 and/or FBXW7 mutated). Although clinical presentations were not significantly associated with NOTCH status, NOTCH þ patients showed a better early response to chemotherapy as compared with NOTCHÀ patients, according to the rate of poor pre-phase 'responders' (25% versus 44%; P ¼ 0.02) and the incidence of high minimal residual disease (MRD) levels (11% (7/62) versus 32% (10/31); P ¼ 0.01) at completion of induction. However, the outcome of NOTCH þ patients was similar to that of NOTCHÀ patients, with a 5-year event-free survival (EFS) of 73% and 70% (P ¼ 0.82), and 5-year overall survival of 82% and 79% (P ¼ 0.62), respectively. In patients with high MRD levels, the 5-year EFS rate was 0% (NOTCH þ ) versus 42% (NOTCHÀ), whereas in those with low MRD levels, the outcome was similar: 76% (NOTCH þ ) versus 78% (NOTCHÀ). The incidence of isolated central nervous system (CNS) relapses was relatively high in NOTCH1 þ patients (8.3%), which could be related to a higher propensity of NOTCH þ leukemic blasts to target the CNS.
Introduction
Childhood T-cell malignancies are aggressive malignancies derived from transformation of T-cell lymphoblastic precursors in the thymus. They include T-cell acute lymphoblastic leukemias (T-ALLs), which account for approximately 15% of acute lymphoblastic leukemias (ALLs), and T-cell lymphoblastic lymphomas, which represent about one-third of non-Hodgkin's lymphomas. Compared with precursor B-ALLs, T-cell malignancies are more likely associated with older age, higher white blood cell count and a mediastinal mass. Formerly associated with a very poor outcome, T-ALL has benefited from more intensive therapies, but has remained less favorable than that of precursor B-ALL. 1 As the classical prognostic factors, such as age and tumor burden criteria, seem to be less predictive of relapse in T-ALL, other markers should be helpful to better discriminate between low-and high-risk patients.
Efforts made in the past decade to understand T-cell oncogenesis led to the identification of a number of genomic abnormalities, which result in the transcriptional deregulation of various oncogenes by active promoters, including those of the T-cell receptor genes. The most frequently deregulated oncogenes encode homeobox and bHLH transcription factors, such as HOX11L2/TLX3 activated by t(5;14)(q35;q32) in 20-25% of cases, TAL1 by SIL-TAL1 microdeletion, and HOX11/TLX1 by T-cell receptor translocations. [2] [3] [4] Gene expression profile studies have shown that specific oncogene deregulation is associated with distinct molecular signatures reflecting a great heterogeneity in T-ALL. 5, 6 The so-called 'classifying' abnormalities that distinguish oncogenic subgroups are recognized in about half of the T-ALL cases.
In addition to these 'classifying' abnormalities, some other oncogenic abnormalities are distributed among T-ALL subtypes in various combinations. They include CDKN2A/p16/ARF inactivation and, more recently, activation of the NOTCH1 signalling pathway.
7 NOTCH1 signalling orchestrates the normal development of T lymphocytes from uncommitted hematopoietic stem cells. 4, 8 NOTCH1 signalling is not only involved in cell fate decision, but also provides an important homeostatic mechanism for survival, proliferation and metabolism of differentiating thymocytes. It has been shown that forced expression of an active form of NOTCH1 in the hematopoietic lineage of mice is sufficient to induce highly aggressive T-cell leukemia 4, [9] [10] [11] [12] [13] and, more importantly, that the NOTCH1 gene is frequently targeted by activating mutations in human T-ALL. 7 NOTCH1 is a single-transmembrane receptor composed of extracellular, transmembrane and intracellular subunits linked via heterodimerization (HD) domains. Ligand binding induces proteolytic cleavage of the receptor by several proteases (including g-secretases), resulting in the release of the intracellular fragment of NOTCH1 (ICN), which translocates to the nucleus and activates target genes. Recent evidence shows that NOTCH1 pathway activation can induce multiple downstream signalling pathways and targets, including the NF-kB pathway and the transcription factor, MYC. Activating mutations of NOTCH1 in T-ALL include mutations at the HD domains, which probably favor ligand-independent cleavage and activation of NOTCH1, and mutations in the proline (P) glutamate (E) serine (E) threonine (T) rich (PEST) domain, which increase the stability of the active ICN form of the protein, as this domain contains in its distal part a degron essential for proteasome-dependent degradation of NOTCH1. More recently, an alternative mechanism of NOTCH1 upregulation has been reported in T-ALL by the loss-of-function of FBXW7 (F-box and WD repeat domain containing 7 isoform). FBXW7 is an E3 ubiquitin ligase responsible for the ubiquitin-mediated degradation of several cell-cycle regulators, including NOTCH1.
14 FBXW7 exerts its function on NOTCH1 by binding the degron located in the PEST domain. FBXW7 mutations abrogating the recognition of NOTCH1 by FBXW7 lead to the inhibition of the degradation of the activated form of NOTCH1. [15] [16] [17] Trials conducted by the Children Leukemia Group of the European Organisation for Research and Treatment of Cancer (EORTC-CLG) are based on Berlin-Frankfurt-Munster-derived protocols. In these trials, genetic abnormalities that were previously investigated showed no prognostic impact, with the exception of a trend toward a favorable outcome for SIL-TAL1 fusion or HOX11/TLX1 overexpression. 18 Thus, risk stratification remained essentially based on early response to chemotherapy, as assessed by the number of blasts in peripheral blood after the pre-phase and, in addition, in the 58951 trial, by the level of minimal residual disease (MRD) at completion of induction therapy. We investigated whether NOTCH1 and/or FBXW7 mutational status could improve the risk stratification in T-ALL. In a cohort of children with T-cell malignancy, enrolled in EORTC trials 58881 and 58951, we evaluated the frequency of NOTCH1 and FBXW7 mutations, their possible relation with a distinct presentation and their potential impact on prognosis.
Patients and methods

Patients and treatment protocol
A cohort of 134 children with newly diagnosed T-cell lymphoblastic leukemias were analyzed. Twelve T-non-Hodgkin's lymphoma (T-NHL) cases were also analyzed for NOTCH1 and FBXW7 mutations, but were not included in the prognosis and response to treatment analyses. All patients were included in the EORTC 58881 (24 patients) or 58951 (122 patients) prospective multicentric trials, 18 between August 1989 and June 2008. Informed consent was provided according to the Declaration of Helsinki. These protocols were accepted by the EORTC Protocol Review Committee and by the Ethics Committee of each participating center.
T-cell lineage and T-ALL subclassification were assessed by immunophenotyping according to the guidelines of the European Group for the Immunological Characterization of Leukemias (EGIL), as previously described, 19 and centrally reviewed. Karyotyping and fluorescence in situ hybridization for MLL rearrangements were performed using standard procedures and centrally reviewed.
MRD monitoring was based on quantitative detection of leukemic clone-specific T-cell-receptor gene rearrangements as previously described. [20] [21] [22] In 58881 and 58951 studies, the VHR group was defined by the presence of any of the following criteria: (i) at completion of the corticosteroid þ intrathecal (IT) methotrexate pre-phase (at day 8), X1000 blasts/mm 3 in the peripheral blood (so-called poor pre-phase 'responders' or PPR); (ii) at completion of induction, failure to achieve complete remission (CR); (iii) in the 58951 study, at completion of induction, failure to achieve a MRD lower than 10
À2
. The VHR group also included ALL with MLL rearrangement.
The treatment regimen of the 58881 trial was adapted from the BFM protocol and was previously described. 18 Main modifications introduced in the 58951 trial for treatment of T-ALL patients were administration of one high dose of methotrexate (5 g/m 2 ) on day 8 and one dose of cyclophosphamide (1g/m 2 ) on day 9. Noteworthy, all patients were randomized on day 1 or day 8 of the pre-phase to receive either prednisolone (60 mg/m 2 / day) or DEX (6 mg/m 2 /day) during induction. The VHR patients in the 58951 study received the same intensified induction course followed by an adaptation of the German BFM high-risk protocol. The central nervous system (CNS)-directed therapy consisted of chemotherapy only, cranial radiation being omitted even for patients with CNS leukemic involvement at diagnosis. IT therapy consisted of methotrexate only on day 1 and triple IT therapy (methotrexate, cytarabine and hydrocortisone) further on. Non-VHR and VHR patients without CNS involvement at diagnosis received, respectively, a total of 16 and 20 IT injections and 11 and 10 intravenous administrations of high-dose of methotrexate. Non-VHR and VHR patients with CNS involvement at diagnosis received at least, respectively, 18 IT and 22 IT injections.
Patients with T-ALL and poor response to the pre-phase or high levels of MRD after induction were eligible for a hematopoietic stem cell transplantation.
Sample preparation for molecular analysis
For each patient, malignant cells were obtained at diagnosis and/or relapse from bone marrow, or, in some cases with lymphoma, from pleural liquid or lymph node punctuates. In case of bone marrow sampling, mononuclear cells were separated by Ficoll centrifugation and the percentage of blasts was evaluated on a cytospin. Only samples with a high percentage of blasts were included in the study. Cell pellets were stored in liquid nitrogen until use. Total RNA and genomic DNA were extracted according to standard procedures.
Expression analysis of oncogenic transcripts by quantitative reverse transcriptase-PCR
RNA extraction and expression analysis of SIL-TAL, TLX1/HOX11 and TLX3/HOX11L2 transcripts were systematically performed as previously described. 18 The presence of NUP214-ABL1 and CALM-AF10 fusions was also assessed for 123 and 103 T-ALL, respectively, by quantitative reverse transcriptase-PCR. CALM-AF10 fusions were detected using a panel of primers and probes, described elsewhere 23 
NOTCH1, FBXW7 and WT1 mutations screening
Mutational screening was performed by direct sequencing of PCR-amplified DNA fragments. NOTCH1 mutations were searched for in the N-terminal region of the heterodimerization domain (HD-N) (exon 26), the C-terminal region of the heterodimerization domain (HD-C) (exon 27), the transcriptional activation domain and the PEST domains (distal part of exon 34). In addition, extracellular juxtamembrane expansion mutations were screened by fluorescent PCR sizing of exon 28, with Jurkat cell line DNA used as a positive control. For FBXW7, mutations in the WD40 domain were searched for by sequencing exon 9 and exon 10. Primer sequences are available on request. WT1 mutations were searched for in exons 7 and 9 as described. 25 Sequencing of PCR products was performed using the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA). Reaction products were run on an automated capillary sequencer (ABI 3130 Genetic Analyzer, Applied Biosystems). Sequences were aligned using Seqscape analysis software (Applied Biosystems) and compared with the reference sequences for genomic DNA and mRNA. GenBank accession numbers for genomic and mRNA reference sequences, respectively, are as follows: WT1 NC_000011.9 and NM_ NM_024426 (isoform d), NOTCH1 NC_000009.11 and NM_017617, FBXW7 NC_000004 and NM_018315. Presence of single-nucleotide polymorphism was checked by consulting the Ensembl genome browser (http:// www.ensembl.org/index.html). Prediction of functional effects of amino-acid substitutions on the function and structure of proteins was achieved by interspecies alignments and using dedicated prediction softwares (Alamut, http://www. interactivebiosoftware.com). Moreover, novel substitutions were checked, when possible, on DNA obtained at complete remission. Somatically acquired substitutions were considered to be associated with leukemogenesis.
Statistical analysis
Event-free survival was calculated from the date of CR to the date of first relapse or death. For patients who failed to reach CR by the end of induction-consolidation, the failure was considered as an event at time 0. All patients alive and in first continuous remission were censored at their last follow-up. The duration of survival was calculated from the date of start of treatment until the date of death; patients still alive were censored at their last follow-up.
Actuarial curves were calculated according to the KaplanMeier technique. The curves were cut at 8 years because too few patients remained at risk beyond that time point; one relapse that occurred at 9 years has therefore not been displayed. The s.e.'s of the estimates were computed using the Greenwood formula. The differences between actuarial curves were tested for statistical significance using the two-tailed logrank test factor stratified by protocol. The Cox proportional hazards model stratified by protocol was used to obtain the estimate and the 95% confidence interval of the hazard ratio of the instantaneous event rate in one group versus the one in another group, as specified by a given variable, and the Wald test was used to determine the prognostic significance. 26 The Cox model was also used to determine the independent prognostic importance of several variables. All analyses were based on the intent-to-treat principle.
The relationship between NOTCH status and covariates with two or more nominal categories was tested for significance using the usual chi-square test (or a Fisher test if needed) and a Kruskall-Wallis test was used for covariates with more than two ordered categories or for continuous variables. Owing to the limited number of patients included, P-values should be interpreted with caution. The cut-off date was November 2003 for the 58881 trial and November 2008 for the 58951 trial. The SAS 9.1 statistical software (SAS Institute Inc., Cary, NC, USA) was used.
Results
NOTCH1 and FBXW7 mutations
The presence of NOTCH1 and FBXW7 mutations was screened in 146 childhood T-cell malignancies. At least one NOTCH1 mutation was identified in 82 cases (56%): 77/134 (57%) T-ALL and 5/12 (42%) T-NHL (Figure 1a and Supplementary Table 1) . Sequences of identified mutations are given in Supplementary Figure S1 . Mutations affecting HD domains were mostly missense mutations at conserved amino-acid positions, or short in-frame insertions or deletions, whereas insertions/deletions resulting in partial or complete deletion were observed in the PEST domain. All NOTCH1 mutations were heterozygous, but up to three mutations in various combinations could be observed (Figure 1) , with two or more being detected in 18 cases (12%). Some mutations were observed at low level despite a high blast count, suggesting that they were acquired as secondary events in a subclone. No extracellular juxtamembrane expansion mutation was observed. FBXW7 mutations were identified in 21 cases (14%): 20/134 T-ALL and 1/12 T-NHL. All mutations were missense mutations at conserved amino-acid positions except one, which was a short insertion resulting in frameshift and premature stop codon. Because of all but three FBXW7-mutated patients having also a NOTCH1 mutation, FBXW7 mutations were mostly associated with NOTCH1 mutation (P ¼ 0.003). Although not strictly exclusive, mutations in the PEST domain of NOTCH1 and mutations of FBXW7 were rarely associated, and FBXW7 mutations were preferentially found in cases with NOTCH1 HD mutations (Figure 1b) . Altogether, a mutation of either NOTCH1 and/or FBXW7 was observed in a total of 85 (58%) T-cell malignancies: 80/134 (60%) T-ALL and 5/12 (42%) T-NHL. 
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In total, 10 T-ALL cases could be analyzed at relapse, including 5 cases with wild type NOTCH1/FBXW7 and 5 cases with NOTCH1 mutations at diagnosis. No mutation was acquired at relapse in the NOTCH1/FBXW7 wild-type T-ALL, while two out of five mutated T-ALL showed modification of their profile of NOTCH1 mutations: one case with a PEST mutation at diagnosis acquired an additional HD mutation (case 58881-1055) and one case with two HD mutations at diagnosis (one HD-N and one HD-C mutations) had only one at relapse (case 58951-950). Noteworthy, these two cases had HOX11L2/ TLX3 overexpression and WT1 mutations, which were conserved at relapse. No change in FBXW7 mutations was observed between diagnosis and relapse in the studied cases.
Characteristics of T-ALL according to NOTCH1/FBXW7 status
The main characteristics of the patients are described in Table 1 . Patients of the study cohort did not significantly differ from the Table 1 Characteristics of patients with T-ALL according to genetic subtypes Prognosis of NOTCH1 activation in childhood T-ALL E Clappier et al whole cohort of patients with T-ALL enrolled in EORTC trials during the same period of time (Supplementary Table 2 ). The clinical and biological features of patients with T-ALL were analyzed according to the presence or absence of NOTCH1 and/or FBXW7 mutations. The study cohort of T-ALL patients was divided into two groups: those displaying a mutation in either NOTCH1 or FBXW7 (further referenced in the text as the NOTCH þ group), and those displaying no mutation of NOTCH1 or FBXW7 (further referenced as the NOTCHÀ group). The characteristics of the NOTCH þ and NOTCHÀ patients' groups are given in Table 1 . The group of FBXW7-mutated T-ALL, irrespective of NOTCH1 mutations, is also described. No significant difference in sex ratio, age at diagnosis, white blood cellcount, and CNS or mediastinal involvement was observed between the NOTCH þ and NOTCHÀ subgroups. NOTCH þ T-ALL tended to be more frequently associated with a cortical phenotype (52% versus 30% in NOTCHÀ cases), whereas NOTCHÀ T-ALL had more often an immature (pro-T or pre-T) phenotype (41% versus 25% in NOTCH þ cases) (P ¼ 0.06) ( Table 1 ). The common oncogenic lesions associated with T-cell oncogenesis, SIL-TAL, HOX11L1/TLX1 and HOX11L2/TLX3 were distributed equally in the NOTCH þ and NOTCHÀ. When analyzed by its own, the subgroup of patients displaying FBXW7 mutations displayed no particular feature as compared with the entire NOTCH þ group (Table 1) .
Prognostic significance of T-ALL according to NOTCH1/FBXW7 status
The group of 134 patients with T-ALL included in the study had event-free survival (EFS) and overall survival rates at 5 years of 72% and 81%, respectively. These outcome data are similar to those observed for the whole population of patients with T-cell malignancies included in the 58881 and 58951 trials during the same period of time (Supplementary Table 2 ).
Four patients did not reach CR. With a median follow-up of 4.5 years, 27 relapsed, 2 died in CR and 101 remained alive in CR. A total of 21 patients died. The outcome of NOTCH þ patients was similar to that of NOTCHÀ patients (Figure 2 ): the 5-year EFS rates were 73 and 70% (P ¼ 0.82), and the 5-year overall survival rates were 82 and 79% (P ¼ 0.62), respectively ( Table 2 ). In the 58951 trial, no difference in EFS or survival was observed according to NOTCH1/FBXW7 status when evaluated separately in patients who had received prednisolone and in those who had received DEX (data not shown).
The impact of NOTCH1/FBXW7 status on early response to treatment was analyzed (Table 3) . NOTCH þ patients showed an overall better response to chemotherapy as compared with NOTCHÀ patients, as they had a lower rate of poor response to the pre-phase (poor pre-phase 'responders', 25% versus 44%; P ¼ 0.02) and a lower incidence of high MRD level (11% versus 32%; P ¼ 0.01). This led to less frequent switch to a VHR protocol for NOTCH þ than for NOTCHÀ patients (29% versus 50%) ( Table 3) . Of note, early response to treatment and outcome of NOTCH þ patients did not differ significantly according to the number of mutations activating the NOTCH pathway (data not shown).
Treatment intensification may have contributed to reduce the difference in outcome between the two groups. However, global analysis of T-ALL in EORTC trials shows that intensification does not allow patients with VHR features to reach the same EFS as standard-risk patients. Therefore, it was unexpected that the 54  39  30  34  19 16  12  6  3  80  63  51  40  35 26  17 14  8   9 54  43 35  26  21 18  13  8  3  12 80  70 55  46  41 Prognosis of NOTCH1 activation in childhood T-ALL E Clappier et al better response to treatment of NOTCH þ patients had no impact on overall outcome. In order to understand this, we examined the prognosis of NOTCH1/FBXW7 status with respect to response to treatment (Figure 3) . Strikingly, in patients with high MRD levels, NOTCH þ patients had a poorer outcome than that of NOTCHÀ patients (5-year EFS was 0% versus 42%, hazard ratio ¼ 4.17, P ¼ 0.05). Therefore, although NOTCH þ patients responded earlier and better to chemotherapy as compared with NOTCHÀ patients, the very poor outcome of NOTCH þ patients with VHR features likely worsened the overall outcome of the NOTCH þ group. Of note, careful examination of the group of NOTCH þ patients who relapsed showed no evidence of additional specific associated oncogenic abnormalities, nor of any particular pattern of NOTCH1 and FBXW7 mutations. 27 Interestingly, although the rate of relapse was similar in both groups, we observed a trend for a different type of relapse according to NOTCH1/FBXW7 status: a higher number of isolated CNS relapses was observed in NOTCH þ as compared with NOTCHÀ patients (6/80 versus 1/54) ( Table 3 ). However, this trend for differences in relapse patterns did not reach statistical significance. Of note, isolated CNS relapses were associated with poor response to pre-phase in only three out of seven cases, to compare with 14 out of 20 patients with bone marrow relapses. A high post-induction MRD level was never observed in patients who had isolated CNS relapse, in line with the lack of MRD power to predict isolated extra-medullary relapses. 28 
Discussion
NOTCH1/FBXW7 mutations pattern in EORTC pediatric trials
In our study, NOTCH1 and/or FBXW7 mutation rate was 60% of T-ALLs, which is in line with previous reports on childhood T-ALL, 7, 26, 29 and confirms a slightly lower incidence in childhood T-ALL compared with adult T-ALL. 30, 31 Activating NOTCH1 mutations and/or FBXW7 mutations were also present in 42% of T-NHLs, in line with our previous finding that T-cell specific alterations that are observed in ALL are also found in lymphoblastic lymphoma. 18 This is consistent with T-ALL and T-NHL representing different hematological presentations of the same disease.
The pattern of NOTCH1 and FBXW7 mutations suggests a stepwise acquisition of additional hits with a dose-dependent effect of NOTCH1 pathway activation on T-cell leukemogenesis and a strong selection pressure for acquired mutations that activate this pathway. Indeed, when mutations are present at both HD and PEST sites, it has been shown that they are always located in cis on the NOTCH1 allele and reporter assays have shown that they induce a synergistic increase in transcriptional activity. 7, 27 FBXW7 mutations were significantly associated with NOTCH1 HD mutations, which suggests that NOTCH pathway activation is their major role in T-cell leukemogenesis. Therefore, NOTCH1-and FBXW7-mutated patients were considered as forming one and the same group, and further analyzed together. FBXW7 mutations were preferentially associated with Table 3 In vivo response to chemotherapy, distribution of types of event and of survival status of T-ALL children according to genetic subgroups Prognosis of NOTCH1 activation in childhood T-ALL E Clappier et al NOTCH1 HD mutations and were rarely seen in association with a PEST mutation. This is consistent with the hypothesis that PEST and FBXW7 mutations both increase the half-life of the intracellular active form of NOTCH1 and are functionally redundant.
We found a higher incidence of NOTCH1/FBXW7 mutations in cortical T-ALL (72%) and a lower incidence in early T-ALL (47%), which is in accordance with some studies, 29 but not with that of van Grotel et al., 26 although the distribution of T-cell differentiation stages found in our series of childhood T-ALL was similar to the latter. Recurrent oncogenic abnormalities mediated by chromosomal translocations are being found in about half of the T-ALL cases. Some of these lesions are mutually exclusive and allow for the definition of T-ALL oncogenic subtypes that correlate with specific stages of T-cell development. 5, 6, 32 In our series, NOTCH1 mutations were found in association with various oncogenic abnormalities. Although we did not find the association of NOTCH1 mutations and TLX3 rearrangements described by Zuurbier et al., 33 the overall frequency of the three most common abnormalities (namely SIL-TAL, HOX11L2/TLX3 and HOX11/TLX1) tended to be higher in the NOTCH þ group, in accordance with a higher frequency of cortical T-ALL. No mutation was found in the four MLL rearranged cases, but this may be due to the small number of cases analyzed, as NOTCH1 mutations have already been reported in T-ALL with MLL-AF6. 7 
Prognosis of NOTCH1/FBXW7 mutations in EORTC trials
Prognosis associated with the presence of NOTCH1 mutation is still to be clarified. In adults, NOTCH1 and/or FBXW7 mutations have been associated either with a favorable 30, 31, 34 or with a pejorative prognosis. 35 In children, NOTCH1 mutations were associated with a favorable outcome in the German BFM 29 and the NOPHO 36 trials, but not in the DCOG ALL-7/8 and ALL-9 studies. 26 In our study, NOTCH þ patients were more frequently good responders to initial chemotherapy, whether evaluated by the number of peripheral blasts after the pre-phase, or by the MRD in the bone marrow after induction. However, NOTCH þ and NOTCHÀ patients did not show a different 5-year EFS or overall survival. We observed that patients with initial poor response to the treatment did worse if they were in the NOTCH þ group. Therefore, although they more often had a good response to initial chemotherapy, the overall group of NOTCH þ patients failed to achieve a higher EFS because the subgroup of those with a poorer initial response were at a much higher risk of relapse, even with treatment intensification. In addition, in NOTCH þ patients, the relatively frequent occurrence of isolated CNS relapses, which are not predicted by current criteria for early response to the treatment, could also partly explain that the good response to treatment of NOTCH þ patients was not associated with a better overall outcome.
In the German BFM trials, NOTCH1 mutation was also associated with lower rate of 'poor response' to chemotherapy, but this translated into a favorable outcome. 29 Notably, NOTCH1À patients had a similar outcome in EORTC and BFM studies (5-year EFS: 70% versus 74%), whereas NOTCH1 þ patients had a lower 5-year EFS in EORTC than in BFM 2000 studies (73% versus 87%).
In the EORTC trials, the rate of isolated CNS relapses was quite higher in NOTCH þ patients as compared with NOTCHÀ patients. Recently, it has been shown in a mouse model that Prognosis of NOTCH1 activation in childhood T-ALL E Clappier et al NOTCH1 positively controls the expression of the chemokine receptor CCR7, an adhesion signal required for targeting T-ALL cells into the CNS. 13 This may explain the higher propensity of NOTCH þ ALL to relapse in the CNS. This excess of isolated CNS relapses was not observed in patients treated according to the BFM protocols (A Kulozik, personal communication). This suggests that some components of the German BFM treatment used less intensively or not at all in the EORTC-BFM version entail a higher therapeutic efficiency in the CNS compartment. With regard to the chemotherapy regimen, dexamethasone, which is known to contribute to the prevention of relapses in the CNS, 37, 38 is the sole cytotoxic agent used in a lower daily dose in EORTC protocols: 6 mg/m 2 in induction for those patients randomized to it and in delayed intensification for all patients, as compared with 10 mg/m 2 in the German BFM. This quantitative difference might at least be partly responsible for the different incidence of CNS relapses. The second factor is the omission of cranial radiotherapy in EORTC patients, whereas this treatment component is to be administered to all T-ALL patients of the German studies. There is evidence that, when evaluated in an overall population of ALL patients receiving optimal CNS-directed chemotherapy, radiotherapy to the cranium may safely be omitted. 28 However, this might not apply to particular subsets of ALL characterized by a more important homing of leukemic cells within the CNS tissues.
Part of the effects of NOTCH1 upregulation can be reproduced by other genetic alterations, such as PTEN loss, p53 inactivation or MYC activation, which are sometimes found in NOTCH1 wild-type T-ALL. 39, 40 Moreover, numerous additional genetic alterations in various combinations participate in T-cell leukemogenesis. Nonetheless, our study, together with that of the accompanying articles from Kox et al. 35 and Zuurbier et al., 33 shows that NOTCH mutation defines a particular group of T-ALL characterized by a more frequent good response to the corticosteroid and IT methotrexate pre-phase and to induction chemotherapy. Association of chemosensitivity with NOTCH1 upregulation is somehow puzzling. Indeed, activated NOTCH1 protects certain T-cell lines from apoptosis induced by dexamethasone or etoposide, through the upregulation of antiapoptotic proteins. 41, 42 More recently, a mechanistic link between NOTCH1 signalling and resistance to glucocorticoids was established by showing that HES1, a transcriptional repressor induced by NOTCH1, represses glucocorticoid receptor auto-upregulation. 43 These mechanisms should favor glucocorticoid resistance by reducing the number of glucocorticoid receptors and by increasing the resistance to apoptosis. However, the opposite effect is observed in NOTCH þ T-ALL, which responds better than NOTCHÀ ones to corticosteroids when these are combined with either IT methotrexate or with induction polychemotherapy. The in vivo effect of NOTCH1 upregulation on the response to glucocorticoids and on apoptosis may thus be more complex than expected. The better early response to chemotherapy in NOTCH þ patients might be related to unknown interactions between NOTCH activation and the mechanism of action of one or several of the other cytotoxic agents. Eventual resistance to chemotherapy in NOTCH þ T-ALL might depend on several parameters, such as the timing of the NOTCH1 mutation, the level of NOTCH1 upregulation, other genetic lesions or the developmental stage of the T-ALL.
In conclusion, although the association of NOTCH1 activation to a favorable early treatment response is constantly observed in pediatric trials, consequences on outcome differ, 33 ,34 probably according to small treatment differences.
These observations underline the close dependence of prognostic factor evaluation on the treatment received.
